CD274 and non-small cell lung carcinoma: Compared with non‐combination therapy, combination radio‐immunotherapy using PD‐1/PD‐L1 inhibitors and RT was significantly associated with longer 1‐year OS (I2 = 0.0%, OR 1.77, 95% CI 1.35–2.33, p = 0.000) and 2‐year OS (I2 = 56.3%, OR 1.77, 95% CI 1.35–2.33, p = 0.000) in patients with advanced NSCLC.